Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
disease activity
disease-modifying therapies
multiple sclerosis
ocrelizumab
relapsing-remitting multiple sclerosis
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
21
10
2021
received:
18
08
2021
accepted:
01
11
2021
pubmed:
9
11
2021
medline:
5
4
2022
entrez:
8
11
2021
Statut:
ppublish
Résumé
Using the treatment goal of "no evidence of disease activity" (NEDA) incorporating magnetic resonance imaging (MRI) re-baselining, we aimed to assess the efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a prior suboptimal response, defined by MRI or relapse criteria, to one or two disease-modifying therapies (DMTs). CASTING was a prospective, international, multicenter, single-arm, open-label phase 3 trial (NCT02861014). Patients (Expanded Disability Status Scale [EDSS] score ≤ 4.0, with discontinued prior DMT of ≥6 months duration due to suboptimal disease control) received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks. The primary endpoint was NEDA (defined as absence of relapses, disability progression, and inflammatory MRI measures, with prespecified MRI re-baselining at Week 8) over 96 weeks. A total of 680 patients were enrolled, 167 (24.6%) based on MRI activity only. At Week 96, 74.8% (95% confidence interval [CI] 71.3-78.0, n/N = 492/658) of patients had NEDA. NEDA was highest among patients enrolled due to MRI activity alone (80.6% [95% CI 68.6-89.6], n/N = 50/62) versus those enrolled for relapse (75.1% [95% CI 69.0-80.6], n/N = 172/229) or for relapse with MRI (70.5% [95% CI 60.0-79.0], n/N = 74/105). NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/408). NEDA was higher in patients receiving one prior DMT (77.6% [95% CI 73.2-81.6], n/N = 312/402) versus two prior DMTs (70.3% [95% CI 64.3-75.8], n/N = 180/256). In patients switching therapy due to suboptimal disease control, treatment with ocrelizumab led to an overall high NEDA rate across a wide range of disease-related and demographic subgroups, regardless of prior treatment background, with no new safety signals detected.
Sections du résumé
BACKGROUND AND PURPOSE
Using the treatment goal of "no evidence of disease activity" (NEDA) incorporating magnetic resonance imaging (MRI) re-baselining, we aimed to assess the efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a prior suboptimal response, defined by MRI or relapse criteria, to one or two disease-modifying therapies (DMTs).
METHODS
CASTING was a prospective, international, multicenter, single-arm, open-label phase 3 trial (NCT02861014). Patients (Expanded Disability Status Scale [EDSS] score ≤ 4.0, with discontinued prior DMT of ≥6 months duration due to suboptimal disease control) received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks. The primary endpoint was NEDA (defined as absence of relapses, disability progression, and inflammatory MRI measures, with prespecified MRI re-baselining at Week 8) over 96 weeks.
RESULTS
A total of 680 patients were enrolled, 167 (24.6%) based on MRI activity only. At Week 96, 74.8% (95% confidence interval [CI] 71.3-78.0, n/N = 492/658) of patients had NEDA. NEDA was highest among patients enrolled due to MRI activity alone (80.6% [95% CI 68.6-89.6], n/N = 50/62) versus those enrolled for relapse (75.1% [95% CI 69.0-80.6], n/N = 172/229) or for relapse with MRI (70.5% [95% CI 60.0-79.0], n/N = 74/105). NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/408). NEDA was higher in patients receiving one prior DMT (77.6% [95% CI 73.2-81.6], n/N = 312/402) versus two prior DMTs (70.3% [95% CI 64.3-75.8], n/N = 180/256).
CONCLUSIONS
In patients switching therapy due to suboptimal disease control, treatment with ocrelizumab led to an overall high NEDA rate across a wide range of disease-related and demographic subgroups, regardless of prior treatment background, with no new safety signals detected.
Identifiants
pubmed: 34748672
doi: 10.1111/ene.15171
pmc: PMC9299209
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ocrelizumab
A10SJL62JY
Banques de données
ClinicalTrials.gov
['NCT02861014']
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
790-801Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
JAMA Neurol. 2019 May 1;76(5):536-541
pubmed: 30776055
Can J Neurol Sci. 2020 Jul;47(4):437-455
pubmed: 32654681
J Neurol. 2019 May;266(5):1182-1193
pubmed: 30820738
Continuum (Minneap Minn). 2019 Jun;25(3):715-735
pubmed: 31162313
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):93-9
pubmed: 25904813
Lancet Neurol. 2020 Dec;19(12):998-1009
pubmed: 33129442
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
J Immunol. 2008 Jan 1;180(1):361-71
pubmed: 18097037
Mult Scler. 2022 Apr;28(5):790-800
pubmed: 34382875
Lancet Neurol. 2020 Apr;19(4):336-347
pubmed: 32059809
Mult Scler. 2009 Jul;15(7):848-53
pubmed: 19542263
Eur J Neurol. 2018 Feb;25(2):215-237
pubmed: 29352526
Biomed J. 2014 Mar-Apr;37(2):41-9
pubmed: 24732658
Eur J Neurol. 2014 Mar;21(3):377-87, e18-20
pubmed: 24237582
Curr Opin Neurol. 2018 Jun;31(3):233-243
pubmed: 29634596
JAMA Neurol. 2015 Feb;72(2):152-8
pubmed: 25531931
BMC Neurol. 2017 Feb 10;17(1):29
pubmed: 28183276
Neurology. 2019 Nov 5;93(19):e1778-e1786
pubmed: 31484710
Neuroimage Clin. 2013 Oct 29;4:10-7
pubmed: 24266007
Lancet Neurol. 2019 Oct;18(10):973-980
pubmed: 31375366
Brain. 2010 Jul;133(Pt 7):1914-29
pubmed: 20534650
Sci Rep. 2020 Aug 28;10(1):14244
pubmed: 32859922
Neurology. 2020 Sep 29;95(13):e1854-e1867
pubmed: 32690791
Neuroimage. 2002 Sep;17(1):479-89
pubmed: 12482100
Mult Scler Relat Disord. 2015 Sep;4(5):460-469
pubmed: 26346796
J Neurol Sci. 2016 Feb 15;361:158-67
pubmed: 26810535
Curr Opin Neurol. 2019 Jun;32(3):365-377
pubmed: 30985372
Lancet. 2011 Nov 19;378(9805):1779-87
pubmed: 22047971
MAbs. 2013 Jan-Feb;5(1):22-33
pubmed: 23211638
Ann Neurol. 2016 Jul;80(1):89-100
pubmed: 27145331
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Eur J Neurol. 2022 Mar;29(3):790-801
pubmed: 34748672
Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642
pubmed: 29568544
Curr Treat Options Neurol. 2021;23(7):19
pubmed: 34025110
N Engl J Med. 2017 Jan 19;376(3):221-234
pubmed: 28002679